GlassScriptPhysician profile
Kerellos A Nasr
NPI 1114236171
$11,681.94
in general payments reported to CMS, 2019-2025
10 companies · $3,673 in 2025
The $3,673 reported for 2025 was more than what 79% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,150 · 2020: $4,153 · 2022: $39.72 · 2023: $2,530 · 2024: $136 · 2025: $3,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,000 · Travel and Lodging: $2,533 · Food and Beverage: $807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,000.00 |
| Travel and Lodging | $2,533.04 |
| Food and Beverage | $806.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Synthes Gmbh | $9,685.85 | 2020-2025 | |
| Medical Device Business Services, INC. | $815.49 | 2019 | |
| Depuy Synthes Sales INC. | $536.53 | 2019-2025 | Na, Fibulink |
| Nuvasive Specialized Orthopedics, INC. | $189.19 | 2019 | |
| Stryker Corporation | $162.04 | 2025 | T2 Alpha |
| Si-Bone, INC. | $124.53 | 2025 | |
| Avita Medical Americas, LLC | $84.00 | 2025 | Cohealyx, Recell, Permeaderm |
| Acera Surgical, INC. | $35.88 | 2025 | Restrata Wound Matrix |
| Orthofix Medical, INC. | $26.78 | 2024 | Cervical-Stim |
| Smith+Nephew, INC. | $21.65 | 2025 | Pico 7 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerellos Nasr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.